Exonics shows CRISPR treats DMD in dogs

Exonics Therapeutics Inc. (Boston, Mass) is one step closer to bringing its SingleCut CRISPR gene editing Duchenne muscular dystrophy treatment to the clinic after preclinical data showed the therapy led to dystrophin restoration of

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE